Delisting riskPopularity #4,171
TCRX · NASDAQ · Biotechnology

TScan Therapeutics (TCRX)

Develops TCR-engineered T-cell therapies for cancer through a T-cell receptor discovery platform.

$0.3571
vs last close+0.00 (+0.65%)